Arcus Biosciences (RCUS) logo

Arcus Biosciences (RCUS) stock

Cancer medicines , market cap $2.3B

After-hours Fri
$15.50
-0.77%

Close $15.62 -1.01%

Why is RCUS down?

Down 8% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.

“The decrease in revenues was primarily driven by lower revenues related to activities under the Gilead Collaboration as they wind down or reach completion”

Arcus Biosciences' Nov 4 release said

Sources: Price history, Nov 5, 2026; Company release, Nov 4, 2026

−2Long-term trend below a falling 200-day average, down over one year

Tell me next time RCUS moves

Free account, no card. An optional alert when RCUS moves or its score changes.Pro, $1 for a first month. An optional alert when RCUS moves or its score changes.Pro, 7 days free with a card. An optional alert when RCUS moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on RCUS →3 more reasons why RCUS fell on Nov 5, from its filings, with the other side, the company's words, the timeline, and its peers, for Pro members.
Quality Score
-7
Poor
In its industry
#214of 273
Checks firing
1of 14
Trending down
From 52-week high
-50.8%
under its best in a year

RCUS's Quality Score fell 1 point on Fri, Nov 20, to -7. Its quiet day ended.

Follow RCUS's trial news. Pro members can get an alert when Arcus Biosciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when RCUS files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026Trial data · SEC filing · Aug 5

Key facts on RCUS

Key facts on RCUS
Holding it backSales down 58% on the year
Latest filing8-K, Nov 4 Reported its quarterly results

RCUS in the news

Big story

Wed Oct 21: Legal

Arcus Biosciences officers face investigation f...

A results day: the move is left out.

Reported by pluang · covered by 2 outlets

What's next

Tue Dec 1: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.

Expected to report Wed Feb 24, after the close

After its last 4 reports it closed -2.5% on average, higher 1 of 4 times.

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

RCUS catalysts

Coming up

5 more coming up and 19 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for RCUS, and how long its cash lasts

Next step the company has named

2026Trial data for Casdatifan, 2026Trial data · SEC filing · Aug 5

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
Casdatifan
Another trial
Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaPhase 3 · Recruiting · 720 people · main data estimated Apr 2028 · NCT07011719

5 more trials, 1 with data due this year, 6 more milestones and 35 filings, for Pro members.

Cash runway

The company says its cash lasts into 2029 (8-K, Nov 4).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Feb 25, 2026)
  • At-the-market share sales program (S-3ASR, filed Feb 25, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Chief Accounting Officer Alexander Azoy sold 2,827 shares on Aug 21, under a planned sale. 5 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Terry Rosen’s 12 filings and quotes.

Get an alert when RCUS files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How RCUS ranks in Biotech

RCUS is #214 of 273 by Quality Score.

How RCUS ranks in Biotech
RankStockQuality Score
214Arcus Biosciences (RCUS) logoRCUSArcus Biosciences-7

Share count against a year before: RCUS +20%, BHVN +43%, XNCR +2.4%, KNSA +4.7%.

More in Biotech

When does RCUS report earnings, and what happens after?

Expected to report Wed Feb 24, after the close (in 95 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What RCUS reported on Nov 4, 2026

The quarter

Sales of $9.0M, 65% less than a year ago; a loss of $1.00 a share, from $1.27.

“The decrease in revenues was primarily driven by lower revenues related to activities under the Gilead Collaboration as they wind down or reach completion, partially offset by increased revenues related to programs under the Taiho Collaboration Agreement.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
License and Development Servicesdown 60%$8M89%$16M39%$20M77%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 4)

1 more line, for Pro members.

The outlook

The outlook the company gave, by period
MeasureFigure
Full year 2026
GAAP revenue$70M to $75Mraised

Figures as filed (SEC filing, Nov 4)

In the company's words

  • “The decrease was due to (i) late-stage development activities decreasing primarily due to the wind-down of Phase 3 studies related to domvanalimab and the completion of enrollment of PRISM-1, partially offset by increasing activities in our Phase 3 studies for casdatifan; (ii) early-stage development activities decreasing primarily due to the wind-down of Phase 2 studies related to domvanalimab and lower Phase 2 study costs for casdatifan; partially offset by (iii) partnership reimbursements decreasing primarily due to a shift towards programs fully funded by us.”

From its results filing (SEC filing · Nov 4)

2 more sentences, for Pro members.

The numbers

Market value
$2.3B
today
Sales
$100M
down 58.3% on the year
Free cash flow
-$466M
last 12 months

Sales grew 30% a year over 3 years, fiscal 2022 to 2025.

Its share count grew 14% a year over 3 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on RCUS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-0.2%+2.3%-8.4%
May 5Aug 5Nov 4
ReportedGapReaction5
days
Nov 4, 2026After close-0.1%-8.4%-2.6%
Aug 5, 2026After close+6.1%+2.3%+4.5%
May 5, 2026After close-4.0%-0.2%-4.5%

RCUS closed higher after 1 of its last 4 reports.

All 4 reports, and RCUS's Quality Score going into each

RCUS sales and profit by year

Sales and profit by year

Sales grew in four of the last five years, to $247M in 2025. It lost money in each of the seven years.

RCUS has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on RCUS, and all 14 on every stock.Get in free →See the top 3 →Start Pro

RCUS RSI on Nov 20: 28.6, below its 50-day and 200-day averages

Not scored

RSI 28.6, MACD below signal, below both averages. Not scored.

The deep dive on RCUS

8 more findings on RCUS, each with its source, for Pro members.

RCUS share count over time

Shares: 19.6% more than a year ago (to Sep 30).

Shares of RCUS outstanding, as filed
Shares
outstanding
As
of
144MOct 29, 2026
127.3MJul 30, 2026
125.8MApr 30, 2026
125.3MFeb 19, 2026
Offerings, shelves, and splits of RCUS, from its filings
From its
filings
Filed
Raised $250M in a sale of shares, about 11% of its market valueOct 22, 2026
Registered shares for a later sale (S-3ASR)Feb 25, 2026
Raised $250M in a sale of shares, about 11% of its market valueOct 31, 2025
Priced a sale of sharesFeb 18, 2025

RCUS insider trades

No insider bought or sold RCUS in the last six months.

RCUS trades by Congress and the executive branch

2 trades disclosed in the last six months. The newest:

SellDonald Trump$1K to $15KPresident (R)traded Jul 29, disclosed Sep 22(55 days later)
All 2 trades on RCUS disclosed by Congress and the executive branch, for Pro members.Get in free →See the top 3 →Start Pro

See what Congress is buying across the market

RCUS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

6 more officers and directors file at RCUS.

See insider trades by person

Which ETFs hold RCUS?

In ETFs: RCUS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Arcus Biosciences

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

601 employeesHayward, CAarcusbio.com

What Arcus Biosciences says it competes with

“The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”

From its annual report, SEC filing · Feb 25, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on RCUS and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn RCUS's score around: 9 things
  • 10 more filings explained, a plain line each
  • 5 more things pulling RCUS's score down
BreakawaySep 22Donald Trump sold RCUS$1K to $15K, disclosed Sep 22

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: RCUS's Quality Score is -7 (Poor), #214 of 273 in Biotech.

What does RCUS's Quality Score say?

RCUS scores -7 today, which Breakaway calls Poor. It is #214 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 8% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Shares: 19.6% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is RCUS's Quality Score?

RCUS scores -7 today, which Breakaway calls Poor (below zero). That is #214 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RCUS's -7.

When does RCUS report earnings?

Expected to report Wed Feb 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. RCUS closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Arcus Biosciences: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.